The FTC, Reverse Payments In The Obama Era

Law360, New York (May 15, 2009, 12:00 AM EDT) -- An impasse is looming in the pharmaceutical industry, and it is poised to provide insight into the approach that the Obama administration takes to antitrust regulation and enforcement.

On one hand, the Federal Trade Commission is taking aim at pharmaceutical companies that settle drug patent litigation on terms that allow the brand company to preserve its monopoly by paying the generic company to drop its patent challenge and take a fixed date of market entry.

On the other hand, private companies want to have the freedom...
To view the full article, register now.